Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

Journal of Chemotherapy

Volumn 25, Issue 1, 2013, Pages 26-31

  Banevicius, Mary A ^a   Kaplan, Nachum ^b   Hafkin, Barry ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Affinium Pharmaceuticals Inc   (Canada)

Author keywords

AFN 1252; Efficacy; Murine; PK PD; S. aureus

Indexed keywords

AFN 1252; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ENZYME INHIBITOR; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PROTEIN BINDING; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BENZOFURANS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PYRONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THIGH;

EID: 84873134560     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000061     Document Type: Article

References (14)

1. Demling RH, Waterhous B. 2007. The increasing problem of wound bacterial burden and infection in acute and chronic soft-tissue wounds caused by methicillin-resistant Staphylococcus aureus. J Burns Wounds. 2007;7:86-98.
2. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Methicillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents. 2012;39:273-82.
3. Mediavilla JR, Chen L, Mathema B, Kreiswirth BN. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA). Curr Opin Microbiol. 2012;15:588-95.
4. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011;66(Suppl.4):iv43-8.
5. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis. 1998;26:1179-81.
6. Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, et al. AFN-1252-Mode of action, in vitro activity and in vivo efficacy of a selective anti-staphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012;56:5865-74.
7. Poutanen S, Pong-Porter S, Rzayev Y, Green K, Willey B, Low D. Susceptibility of clinical S. aureus to API-1252, a novel enoyl-ACP reductase (FabI) inhibitor [abstract F1-0755]. 46th ICAAC, San Francisco, CA, Sep 2006.
8. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard M7-A7. Wayne, PA: CLSI; 2006.
9. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the post-antibiotic effect of imipenem. Antimicrob Agents Chemother. 1997;41:345-51.
10. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to break-point determinations. Antimicrob Agents Chemother. 1998;42:2375-9.
11. Kaplan N, Hafkin B. In vitro and in vivo absorption properties of AFN-1252, a novel specific-spectrum anti-staphylococcal agent [poster F1-2005]. 49th ICAAC, San Francisco, CA, Sep 2009.
12. Kaplan N, Flanner H, Hafkin B. Correlation of AFN-1252 Phase 0 microdosing and Phase 1 pharmacokinetics [poster F1-2006]. 49th ICAAC, San Francisco, CA, Sep 2009.
13. Karlowsky J, Laing M, Baudry T, Kaplan N, Vaughan D, Hoban D, et al. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 2007;51:1580-1.
14. Karlowsky J, Kaplan N, Hafkin B, Hoban D, Zhanel G. APF-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother. 2009; 53:3544-8.